All authors declare no conflict of interest.
Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation
Version of Record online: 25 AUG 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Special Issue: BRCA1 and BRCA2
Volume 85, Issue 1, pages 21–30, January 2014
How to Cite
Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation., , , , .
- Issue online: 12 DEC 2013
- Version of Record online: 25 AUG 2013
- Accepted manuscript online: 16 JUL 2013 10:52AM EST
- Manuscript Revised: 4 JUL 2013
- Manuscript Accepted: 4 JUL 2013
- Manuscript Received: 4 APR 2013
- Canadian Institutes of Health Research
- Ontario Women's Health Council
- BRCA1 mutation;
- BRCA2 mutation;
- cancer risk;
- health care provider recommendations
There is a significant variation in the uptake of cancer risk reducing options by women with a BRCA1 or BRCA2 mutation. It is currently unclear why these differences exist and it is possible that recommendations vary between providers and these influence patient decisions. Eligible health care providers who provide genetic counseling for hereditary breast and ovarian cancer families in Canada were identified. Each provider was asked to complete a study specific questionnaire that included their opinion of various cancer risk reduction options and their recommendations for specific cases. Respondents recommended prophylactic oophorectomy more often than prophylactic mastectomy or tamoxifen for women with a BRCA1 or BRCA2 mutation (p < 0.0001). Fewer than half of the respondents agreed with the recommendation for prophylactic mastectomy, and a minority of the respondents supported the recommendation for tamoxifen for chemoprevention. The majority of Canadian genetics health care providers adhere to the National Comprehensive Cancer Network (NCCN) Guideline of recommending prophylactic oophorectomy to mutation carriers, however, the minority of genetics health care providers recommend either prophylactic mastectomy or tamoxifen.